The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
CRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells
Open accessAbstract
The β-haemoglobinopathies, such as sickle cell disease and β-thalassaemia, are caused by mutations in the β-globin (HBB) gene and affect millions of people worldwide. Ex vivo gene correction in patient-derived haematopoietic stem cells followed by autologous transplantation could be used to cure β-haemoglobinopathies. Here we present a CRISPR/Cas9 gene-editing system that combines Cas9 ribonucleoproteins and adeno-associated viral vector delivery of a homologous donor to achieve homologous recombination at the HBB gene in haematopoietic stem cells. Notably, we devise an enrichment model to purify a population of haematopoietic stem and progenitor cells with more than 90% targeted integration. We also show efficient correction of the Glu6Val mutation responsible for sickle cell disease by using patient-derived stem and progenitor cells that, after differentiation into erythrocytes, express adult β-globin (HbA) messenger RNA, which confirms intact transcriptional regulation of edited HBB alleles. Collectively, these preclinical studies outline a CRISPR-based methodology for targeting haematopoietic stem cells by homologous recombination at the HBB locus to advance the development of next-generation therapies for β-haemoglobinopathies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Accordingly, several reports have shown efficient Glu6Val correction in SCD-HSPCs, although correction efficiency can sometimes be linked with off-target INDELs in the same edited population15,16,45,46.”
From A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells (2018) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“RNP delivery results in an initially high level of the genome editing machinery followed by rapid decay, leading to a “fast on, fast off” strategy that results in highly efficient editing while minimizing OTEs13–19.”
From A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells (2018) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“AAV6 homologous donor DNA templates are an efficient way to deliver donor templates for sensitive primary immune cells, including HSPCs and T-Cells15,35–40.”
From A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells (2018) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recent studies have shown that disease-causing genetic errors can be corrected using CRISPR/Cas9 in long-term engrafting HSPCs that are preserved in downstream effector lineages15,16,24,25.”
From A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells (2018) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Major progress in delivering to 44 and handling HPSCs has resulted in formidable efficiencies of mutation correction or mitigation 18,45-47 that are expected to be curative.”
From The promise and challenge of therapeutic genome editing (2020) · cites this paper as [45]
Experimental — accuracy not yet measured
In the citing paper
“Furthermore, CRISPR/Cas9 system holds tremendous promise for gene therapy [46–51]. It can correct causal mutations in the original genome and rescue the disease phenotypes of monogenic disorders permanently, which currently represents the most translatable field in CRISPR/Cas9-mediated disease therapy.”
From Non-viral delivery systems for CRISPR/Cas9-based genome editing: challenges and opportunities (2018) · cites this paper as [49]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
The new frontier of genome engineering with CRISPR-Cas9
Doudna, J. A., & Charpentier, E. (2014) · Science · doi:10.1126/science.1258096 · Cited by 7,062
Development and Applications of CRISPR-Cas9 for Genome Engineering
Hsu, P. D., Lander, E. S., & Zhang, F. (2014) · Cell · doi:10.1016/j.cell.2014.05.010 · Cited by 5,762
Easy quantitative assessment of genome editing by sequence trace decomposition
Brinkman, E. K., Chen, T., Amendola, M., & van Steensel, B. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku936 · Cited by 2,390
Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia
Cavazzana-Calvo, M., Payen, E., Negre, O., Wang, G., Hehir, K., Fusil, F., Down, J., Denaro, M., Brady, T., Westerman, K., et al. (2010) · Nature · doi:10.1038/nature09328 · Cited by 1,276
Gene therapy returns to centre stage
Naldini, L. (2015) · Nature · doi:10.1038/nature15818 · Cited by 1,184
HSV-TK Gene Transfer into Donor Lymphocytes for Control of Allogeneic Graft-Versus-Leukemia
Bonini, C., Ferrari, G., Verzeletti, S., Servida, P., Zappone, E., Ruggieri, L., Ponzoni, M., Rossini, S., Mavilio, F., Traversari, C., et al. (1997) · Science · doi:10.1126/science.276.5319.1719 · Cited by 1,158
Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells
Hendel, A., Bak, R. O., Clark, J. T., Kennedy, A. B., Ryan, D. E., Roy, S., Steinfeld, I., Lunstad, B. D., Kaiser, R. J., Wilkens, A. B., et al. (2015) · Nature Biotechnology · doi:10.1038/nbt.3290 · Cited by 1,090
Self-citationIsolation of a candidate human hematopoietic stem-cell population.
Baum, C. M., Weissman, I. L., Tsukamoto, A. S., Buckle, A., & Péault, B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.7.2804 · Cited by 1,084
Hematopoietic stem cell: self‐renewal versus differentiation
Seita, J., & Weissman, I. L. (2010) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.86 · Cited by 997
Flagged first, then by citations
Cited by
Sorted by citations
Items 601–700 of 864
Li, J., Tang, C., Liang, G., Tian, H., Lai, G., Wu, Y., Liu, S., Zhang, W., Liu, S., & Shao, H. (2023) · Human Gene Therapy · doi:10.1089/hum.2023.115 · Cited by 7
Gene regulation in inborn errors of immunity: Implications for gene therapy design and efficacy
Ghanim, H. Y., & Porteus, M. H. (2024) · Immunological Reviews · doi:10.1111/imr.13305 · Cited by 7
Self-citationCRISPR technology in human diseases
Feng, Q., Li, Q., Zhou, H., Wang, Z., Lin, C., Jiang, Z., Liu, T., & Wang, D. (2024) · MedComm · doi:10.1002/mco2.672 · Cited by 8
Araujo, A. E., Bentler, M., Garmendia, X. P., Kaleem, A., Fabian, C., Morgan, M. A., Hacker, U. T., & Büning, H. (2024) · Human Gene Therapy · doi:10.1089/hum.2024.114 · Cited by 7
Ritter, M. U., Nasri, M., Dannenmann, B., Mir, P., Secker, B., Amend, D., Klimiankou, M., Welte, K., & Skokowa, J. (2024) · The CRISPR Journal · doi:10.1089/crispr.2024.0006 · Cited by 7
Nam, H., Xie, K., Majumdar, I., Wang, J., Yang, S., Starzyk, J., Lee, D., Shan, R., Li, J., & Wu, H. (2025) · Nature Communications · doi:10.1038/s41467-025-59790-3 · Cited by 8
Gene Correction of Point Mutations Using PolyPurine Reverse Hoogsteen Hairpins Technology
Félix, A. J., Solé, A. S., Noé, V., & Ciudad, C. J. (2020) · Frontiers in Genome Editing · doi:10.3389/fgeed.2020.583577 · Cited by 7
Essawi, K., Hakami, W., Khan, M. B. N., Martin, R., Zeng, J., Chu, R., Uchida, N., Bonifacino, A. C., Krouse, A. E., Linde, N. S., et al. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.04.004 · Cited by 9
Self-citationA systematic review of clinical trials for gene therapies for β-hemoglobinopathy around the world
Rós, F. A., Couto, S. C. F., Milhomens, J., Ovider, I., Tozatto‐Maio, K., Jennifer, V., Ramos, R. N., Picanço‐Castro, V., Kashima, S. H., Calado, R. T., et al. (2023) · Cytotherapy · doi:10.1016/j.jcyt.2023.05.006 · Cited by 9
Genome editing technologies and their potential to treat neurologic disease
Madigan, N. N., Staff, N. P., Windebank, A. J., & Benarroch, E. E. (2017) · Neurology · doi:10.1212/wnl.0000000000004558 · Cited by 7
Lamsfus‐Calle, A., Daniel-Moreno, A., Ureña-Bailén, G., Rottenberger, J., Raju, J., Epting, T., Marciano, S., Heumos, L., Baskaran, P., Antony, J. S., et al. (2021) · The CRISPR Journal · doi:10.1089/crispr.2020.0141 · Cited by 9
Liu, Q., Li, X., Xu, H., Luo, Y., Cheng, L., Liang, J., He, Y., Liu, H., Fang, J., & Huang, J. (2025) · Advanced Biotechnology · doi:10.1007/s44307-024-00053-5 · Cited by 6
Charlesworth, C. T., Homma, S., Amaya, A. K., Dib, C., Vaidyanathan, S., Tan, T.-K., Miyauchi, M., Nakauchi, Y., Suchy, F. P., Wang, S., et al. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101438 · Cited by 6
Wolff, J. H., Skov, T. W., Haslund, D., Dorset, S. R., Revenfeld, A. L., Aussel, C., Jørgensen, S. E., Holm, M., Thomsen, M. K., Ammann, S., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-62738-2 · Cited by 9
Self-citationCRISPR-Cas technologies: Emerging tools from research to clinical application
Hyeon, H., Hwang, S., Luo, Y., Shin, E., Yeom, J., Kim, H., Ryu, M., & Lee, K. (2025) · The Journal of Microbiology · doi:10.71150/jm.2504012 · Cited by 7
Kansal, R. (2025) · Genes · doi:10.3390/genes16111367 · Cited by 6
MDM2 antagonists promote CRISPR/Cas9-mediated precise genome editing in sheep primary cells
Li, Y., Lian, D., Wang, J., Zhao, Y., Li, Y., Liu, G., Wu, S., Deng, S., Du, X., & Lian, Z. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.12.020 · Cited by 6
Multi-faceted CRISPR/Cas technological innovation aspects in the framework of 3P medicine
Lučanský, V., Holubeková, V., Kolková, Z., Halášová, E., Samec, M., & Golubnitschaja, O. (2023) · The EPMA Journal · doi:10.1007/s13167-023-00324-6 · Cited by 6
Zhang, L., Li, K., Liu, Z., An, L., Wei, H., Pang, S., Cao, Z., Huang, X., Jin, X., & Ma, X. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.03.028 · Cited by 6
A critical review of therapeutic interventions in sickle cell disease: Progress and challenges
Chandu, A., Joshi, R. P., Gupta, P., Goswami, S. G., Ramalingam, S., Gowri, C. S. K. V., & Murugesan, S. (2024) · Archiv der Pharmazie · doi:10.1002/ardp.202400381 · Cited by 6
Current progress in CRISPR-Cas systems for rare diseases
Israr, J., & Kumar, A. (2024) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2024.07.019 · Cited by 7
Genome editing-based approaches for imaging protein localization and dynamics in the mammalian brain
Mikuni, T. (2019) · Neuroscience Research · doi:10.1016/j.neures.2019.04.007 · Cited by 5
Shen, L., Garay, J. P., Tubbs, C. A., & Franco, H. L. (2021) · FEBS Open Bio · doi:10.1002/2211-5463.13139 · Cited by 7
Medical care of rare and undiagnosed diseases: Prospects and challenges
Shan, Z., Ding, L., Zhu, C., Sun, R., & Hong, W. (2022) · Fundamental Research · doi:10.1016/j.fmre.2022.08.018 · Cited by 7
Enabling Precision Medicine with CRISPR-Cas Genome Editing Technology: A Translational Perspective
Ilahibaks, N. F., Hulsbos, M. J., Lei, Z., Vader, P., & Sluijter, J. P. G. (2022) · Advances in experimental medicine and biology · doi:10.1007/978-981-19-5642-3_20 · Cited by 7
Benati, D., Leung, A., Perdigão, P. R. L., Toulis, V., van der Spuy, J., & Recchia, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232315276 · Cited by 7
Genome editing and cancer therapy: handling the hypoxia-responsive pathway as a promising strategy
Stampone, E., Bencivenga, D., Capellupo, M. C., Roberti, D., Tartaglione, I., Perrotta, S., Ragione, F. D., & Borriello, A. (2023) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-023-04852-2 · Cited by 6
Whittaker, T. E., Moula, S. E., Bahal, S., Bakri, F. G., Hayajneh, W. A., Daoud, A. K., Naseem, A., Cavazza, A., Thrasher, A. J., & Santilli, G. (2023) · Human Gene Therapy · doi:10.1089/hum.2023.114 · Cited by 5
Engineering precision therapies: lessons and motivations from the clinic
Xie, M., Viviani, M., & Fussenegger, M. (2020) · Synthetic Biology · doi:10.1093/synbio/ysaa024 · Cited by 6
Lung development, repair and cancer: A study on the role of MMP20 gene in adenocarcinoma
Mok, P. L., Anandasayanam, A. N. K., David, H. M. O., Tong, J., Farhana, A., Khan, M. S. A., Sivaprakasam, G., Koh, A. E.-H., & Alzahrani, B. (2021) · PLoS ONE · doi:10.1371/journal.pone.0250552 · Cited by 6
Get ready for the CRISPR/Cas system: A beginner's guide to the engineering and design of guide RNAs
Ma, S., Lv, J., Feng, Z., Rong, Z., & Lin, Y. (2021) · The Journal of Gene Medicine · doi:10.1002/jgm.3377 · Cited by 8
Reactivation of γ-globin expression using a minicircle DNA system to treat β-thalassemia
Ma, S., Gao, X.-X., Zhou, G., Zhang, H., Yang, J.-M., Wang, W., Song, X., Chen, H., & Lu, D. (2022) · Gene · doi:10.1016/j.gene.2022.146289 · Cited by 6
Guerra, A., Musallam, K. M., Taher, A. T., & Rivella, S. (2017) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2017.11.002 · Cited by 6
Genome editing for blood disorders: state of the art and recent advances
Romito, M., Rai, R., Thrasher, A. J., & Cavazza, A. (2019) · Emerging Topics in Life Sciences · doi:10.1042/etls20180147 · Cited by 7
Hemoglobinopathies due to structural mutations
Layton, D. M., & Okoli, S. (2019) · Wiley eBooks · doi:10.1002/9781119252863.ch14 · Cited by 6
Bozhilov, Y. K., Brown, E., Hsu, I., Singh, I., Rodriguez-Fraticelli, A., Roy, A., Yamazaki, S., & Wilkinson, A. C. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.09.17.613552 · Cited by 6
SNA·SMNP·CBE system: A novel integrative strategy for β-hemoglobinopathies gene therapy
Cheng, H., Hui, W., Kang, H., Shi, Z., Liu, J., Wang, X., Qi, F., Mao, L., Ding, H., Hu, R., et al. (2024) · Nano Today · doi:10.1016/j.nantod.2024.102558 · Cited by 5
Skov, T. W., Wolff, J. H., Haslund, D., Revenfeld, A. L., van de Venn, L., Dorset, S. R., Ravendran, S., Jørgensen, S. E., Thomsen, M. K., Holm, M., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.07.038 · Cited by 6
Self-citationTargeted Intracellular Delivery via Precision Programming of ARRDC1‐Mediated Microvesicles
Qiao, Z., Choi, S., Chen, Z., Rodriguez, R. M., Wang, Q., Yang, Z., Theuerkauf, S. A., Nabhan, J. F., Hensch, T. K., Buchholz, C. J., et al. (2025) · Journal of Extracellular Vesicles · doi:10.1002/jev2.70199 · Cited by 6
Canarutto, D., Fiumara, M., Venkatesan, V., Gaddoni, C., Shiroshita, K., Varesi, A., Albano, L., Pelosi, G., Silva, A., Firrito, C., et al. (2026) · Nature Biotechnology · doi:10.1038/s41587-026-03142-z · Cited by 5
Development of a riboflavin-responsive model of riboflavin transporter deficiency in zebrafish
Choueiri, C. M., Lau, J., O’Connor, E., DiBattista, A., Wong, B. Y., Spendiff, S., Horváth, R., Pena, I. A., MacKenzie, A., & Lochmüller, H. (2024) · Human Molecular Genetics · doi:10.1093/hmg/ddae171 · Cited by 5
Akazawa, Y., Vaidyanathan, S., Dewar, M. B., Yazaki, K., Dauz, J. D., Honjo, O., Sun, M., Kabir, G., Jankov, R. P., Heximer, S. P., et al. (2024) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2024.10.007 · Cited by 5
Development of Inorganic and Hybrid Nanosystems for Delivery of CRISPR-Based Gene Editors
Spataru, I. A., Mahoro, F., & Badea, I. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c00251 · Cited by 6
Ser/Thr protein kinase Bβ-NADPH oxidase 2 signaling in thromboinflammation
Li, J., & Cho, J. (2017) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000365 · Cited by 5
Viral delivery of genome-modifying proteins for cellular reprogramming
Mikkelsen, J. G. (2018) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2018.06.005 · Cited by 6
Lung stem cells and therapy for cystic fibrosis
Vaidyanathan, S., McCarra, M. B., & Desai, T. (2021) · European Respiratory Society eBooks · doi:10.1183/2312508x.10010520 · Cited by 5
Qing, Y., Gao, L., Han, L., Su, R. J., & Chen, J. (2021) · STAR Protocols · doi:10.1016/j.xpro.2021.100603 · Cited by 5
Peterson, C. W., Venkataraman, R., Reddy, S. S., Pande, D., Enstrom, M., Radtke, S., Humbert, O., & Kiem, H. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.11.010 · Cited by 7
Therapeutic targeting and HSC proliferation by small molecules and biologicals
Albayrak, E., & Kocabaş, F. (2023) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2022.11.012 · Cited by 5
Sconocchia, T., Foßelteder, J., Köhnke, T., Majeti, R., & Reinisch, A. (2023) · Journal of Visualized Experiments · doi:10.3791/64558 · Cited by 8
Self-citationLotfi, M., Ashouri, A., Mojarrad, M., Mozaffari‐Jovin, S., & Abbaszadegan, M. R. (2023) · Molecular Biotechnology · doi:10.1007/s12033-023-00739-6 · Cited by 5
A New Chapter on Targeted Gene Insertion for X-CGD: Do Not Skip the Intro(n)
Santilli, G., & Thrasher, A. J. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.01.002 · Cited by 5
Pressing diseases that represent promising targets for gene therapy.
Beitelshees, M., Hill, A. B., Rostami, P., Jones, C. H., & Pfeifer, B. A. (2017) · PubMed · Cited by 6
Corrigendum: Targeted Gene Delivery: Where to Land
Pavani, G., & Amendola, M. (2021) · Frontiers in Genome Editing · doi:10.3389/fgeed.2021.682171 · Cited by 5
Luna, S. E., Camarena, J., Hampton, J. P., Majeti, K. R., Charlesworth, C. T., Soupène, E., Selvaraj, S., Jia, K., Sheehan, V., Cromer, M. K., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.08.04.552064 · Cited by 5
Self-citationSecreted Particle Information Transfer (SPIT) – A Cellular Platform for In Vivo Genetic EngineeringPreprint
Charlesworth, C. T., Homma, S., Suchy, F. P., Wang, S., Bhadury, J., Amaya, A. K., Camarena, J., Zhang, J., Tan, T.-K., Igarashi, K. J., et al. (2024) · Research Square · doi:10.1101/2024.01.11.575257 · Cited by 6
Self-citationA unified genetic perturbation language for human cellular programmingPreprint
Hartman, A., Takacsi-Nagy, O., Kernick, C., Theberath, N. E., Lu, J., Wu, L., Mantilla, M., Mittra, S., McClellan, A. K., Johnson, N., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.20.689421 · Cited by 6
Hunt, J., du Rand, A., Verdon, D. J., Clemance, L., Loef, E. J., Malhi, C., Buttle, B., Knapp, D. J. H. F., Michaels, Y. S., Garlick, J. A., et al. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102472 · Cited by 4
Zeng, J., Diao, L., Xie, S., & Xiao, Z. (2025) · Cell investigation. · doi:10.1016/j.clnves.2025.100047 · Cited by 4
Almasoudi, H. H. (2025) · Current Research in Translational Medicine · doi:10.1016/j.retram.2025.103513 · Cited by 5
The racial politics of visibility and equity in genome-editing therapies for sickle cell disease
Molina, S. J., & Creary, M. (2025) · Social Science & Medicine · doi:10.1016/j.socscimed.2025.118452 · Cited by 4
Hematopoietic stem cell therapy with gene modification to treat sickle cell disease
Ball, J., Bradley, A., Le, A., Tisdale, J. F., & Uchida, N. (2025) · Stem Cells Translational Medicine · doi:10.1093/stcltm/szaf042 · Cited by 7
Self-citationLetort, G., Duclert, A., Clerre, D. L., Chion-Sotinel, I., Salvatori, R., Dessez, E., Sevin, M., Rotondi, M. C., Ducani, C., Duchateau, P. N., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-66318-2 · Cited by 4
mGem: AAV, from almost a virus to an awesome vector—or is it?
Srivastava, A. (2026) · mBio · doi:10.1128/mbio.02957-25 · Cited by 5
Rathbone, T., Ates, I., Stuart, C., Parker, T., & Cottle, R. N. (2022) · Journal of Visualized Experiments · doi:10.3791/63828 · Cited by 7
High level of fetal-globin reactivation by designed transcriptional activator-like effector
Zhan, J., Irudayam, M. J., Nakamura, Y., Kurita, R., & Nienhuis, A. W. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019000482 · Cited by 4
Extensive humoral immune response to AAVs and Cas proteins in nonhuman primates
Xiao, P., Bai, R., Zhang, T., Zhou, Y., Zhou, Z., Zhuo, Y., Gong, N., Niu, Y., Ren, S., Wu, R., et al. (2021) · 中国科学通报：英文版 · doi:10.1016/j.scib.2021.02.009 · Cited by 4
Chupradit, K., Thongsin, N., Tayapiwatana, C., & Wattanapanitch, M. (2022) · PLoS ONE · doi:10.1371/journal.pone.0270963 · Cited by 4
The CRISPR Revolution in the Drug Discovery Workflow: An Industry Perspective
Lattanzi, A., & Maddalo, D. (2022) · The CRISPR Journal · doi:10.1089/crispr.2022.0002 · Cited by 4
Quezada‐Ramírez, M. A., Loncar, S., Campbell, M. A., Parsi, K. M., Gifford, R. J., & Kotin, R. M. (2025) · iScience · doi:10.1016/j.isci.2025.113910 · Cited by 4
A topography of immunotherapies against gastrointestinal malignancies
DHASMANA, A., DHASMANA, S., Kotnala, S., ANUKRITI, A., Kashyap, V. K., SHAJI, P. D., Laskar, P., Sheema, K. H. A. N., PELLICANO, R., Fagoonee, S., et al. (2021) · Panminerva Medica · doi:10.23736/s0031-0808.21.04541-9 · Cited by 4
CRISPR/Cas9 Gene Editing In Vitro and in Retinal Cells In Vivo
Benati, D., Marigo, V., & Recchia, A. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8669-9_4 · Cited by 4
CRISPR-Click Enables Dual-Gene Editing with Modular Synthetic sgRNAs
Park, H., Osman, E. A., Cromwell, C. R., Laurent, C. D. S., Liu, Y., Kitova, E. N., Klassen, J. S., Hubbard, B. P., Macauley, M. S., & Gibbs, J. M. (2022) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.2c00106 · Cited by 4
Vaidyanathan, S., Salahudeen, A. A., Sellers, Z. M., Bravo, D. T., Choi, S. S., Batish, A., Le, W., Sean de la, O., Kaushik, M. P., Galper, N., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/561183 · Cited by 4
Self-citationA Single Cell Cloning Platform for Gene Edited Functional Murine Hematopoietic Stem CellsPreprint
Becker, H., Ishida, R., Wilkinson, A. C., Kimura, T., Lee, M. S. J., Coban, C., Ota, Y., Tojo, A., Kent, D. G., & Yamazaki, S. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.03.23.485423 · Cited by 4
Tafech, B., Carlaw, T., Sadhnani, G., Schmidt, K., Morin, T., Leung, J., Weiner, J. M., An, K., Balázs, A., Ross, C. J., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114053 · Cited by 6
Mengistu, G. (2026) · The Journal of Gene Medicine · doi:10.1002/jgm.70091 · Cited by 4
Applications of genome editing technologies in the treatment of human diseases
Alshorman, J., Mehran, M. J., Tembo, K. M., Mostafavi, N., Bolideei, M., & Wang, Y. L. (2026) · Gene Therapy · doi:10.1038/s41434-026-00627-z · Cited by 3
Chen, Y., Banie, L., Breyer, B. N., Tan, Y. L., Wang, Z., Zhou, F., Wang, G., Lin, G., Liu, J., Qi, L. S., et al. (2022) · The CRISPR Journal · doi:10.1089/crispr.2022.0009 · Cited by 3
Genetic Editing with CRISPR Cas9: recent Biomedical and Biotechnological Applications
Posse, F., Peña, A. K. P., Velásquez, C. A. R., Virgüez, M. C. M., & Méndez, J. A. G. (2024) · Universitas Scientiarum · doi:10.11144/javeriana.sc291.gewc · Cited by 4
Applications of gene modification technologies in the treatment of inherited diseases
Superson, M., Szmyt, K., Wilk-Trytko, K., Krasnoborska, J., Samojedny, S., Szymańska, K., & Walczak, K. (2024) · Journal of Education Health and Sport · doi:10.12775/jehs.2024.66.002 · Cited by 3
Circadian Clock Gene Bmal1: A Molecular Bridge from AKI to CKD
Yang, S., Ye, Z., Chen, L., Zhou, X., Li, W., & Fan, C. (2025) · Biomolecules · doi:10.3390/biom15010077 · Cited by 3
Targeted gene therapy into a safe harbor site in human hematopoietic progenitor cells
Rodríguez-Fornés, F., Bustamante, O. Q., Lozano, M. L., Segovia, J. C., Bueren, J. A., & Güenechea, G. (2020) · Gene Therapy · doi:10.1038/s41434-020-0144-x · Cited by 3
Selvaraj, D., Dawar, R., Kumar, S. P., & Devi, A. (2021) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2021-0062 · Cited by 3
Wang, L., Siwko, S. K., & Li, D. (2023) · Life Medicine · doi:10.1093/lifemedi/lnad009 · Cited by 3
Fañanas-Baquero, S., Morin, M., Fernández, S., Ojeda-Pérez, I., Dessy-Rodríguez, M., Giurgiu, M., Bueren, J. A., Moreno-Pelayo, M. Á., Segovia, J. C., & Bustamante, O. Q. (2023) · Frontiers in Genome Editing · doi:10.3389/fgeed.2023.1104666 · Cited by 3
Prime editing and its application in beta-hemoglobinopathies
Das, S. S. (2024) · The Nucleus · doi:10.1007/s13237-024-00470-w · Cited by 4
Gao, C., Song, Q., Zhang, M., Li, J., Miao, Y., Li, Z., & Dong, J. (2020) · Molecular Immunology · doi:10.1016/j.molimm.2020.05.007 · Cited by 3
Key to Delivery: The (Epi-)genome Editing Vector Toolbox
Just, S., & Büning, H. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7774-1_7 · Cited by 3
Manufacturing and Delivering Genome-Editing Proteins
Liu, J., Liang, Y.-J., Ren, P.-L., & Gaj, T. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8799-3_19 · Cited by 3
Editing the Genome Ex Vivo Stem Cell Therapy
Fan, Y., & Chan, J. K. Y. (2018) · Current Stem Cell Reports · doi:10.1007/s40778-018-0148-2 · Cited by 3
Daniel-Moreno, A., Lamsfus‐Calle, A., Wilber, A. C., Chambers, C. B., Johnston, I., Antony, J. S., Epting, T., Handgretinger, R., & Mezger, M. (2020) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2020.102456 · Cited by 3
Computational tools and scientometrics for CRISPR-based genome editing
Balakrishnan, M., Kotla, A., Agarwal, S., Krishnan, P., Purru, S., & Srinivasarao, C. (2023) · Journal of Plant Biochemistry and Biotechnology · doi:10.1007/s13562-023-00853-1 · Cited by 3
Managing cell and human identity
Moreno, J. D., Gearhart, J. D., Zoloth, L., Pyeritz, R. E., & Zaret, K. S. (2017) · Science · doi:10.1126/science.aan2763 · Cited by 3
Doerfler, W. (2019) · Epigenomics · doi:10.2217/epi-2018-0201 · Cited by 3
Chu, S. N., Soupène, E., Wienert, B., Yin, H., Sharma, D., McCreary, T., Jia, K., Homma, S., Hampton, J. P., Gardner, J. M., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.09.01.555926 · Cited by 3
Self-citationGenome engineering with Cas9 and AAV repair templates, successes and pitfalls
Birling, M., Hérault, Y., & Pavlovic, G. (2025) · Mammalian Genome · doi:10.1007/s00335-024-10099-4 · Cited by 3
Khaseb, S., Karimi, R., Tavangar, F., Taghipour, N., & Atashi, A. (2025) · Molecular Biology Reports · doi:10.1007/s11033-025-10730-w · Cited by 2
Emerging Therapies for Sickle Cell Disease: From Symptom Management to Curative Gene Therapy
Duesberg, M., & Schiller, G. J. (2025) · Cureus · doi:10.7759/cureus.95112 · Cited by 3
Ojeda-Pérez, I., Bustos, A., Selvaraj, S., Fañanas-Baquero, S., Alberquilla, O., Serrano, L.-J., Bonafont, J., García-Torralba, A., Torres-Ruiz, R., Rodríguez, S., et al. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101615 · Cited by 3
Self-citation
Metadata
- Authors
- Dever, D. P., Bak, R. O., Reinisch, A., Camarena, J., Washington, G., Nicolas, C. E., Pavel-Dinu, M., Saxena, N., Wilkens, A. B., Mantri, S., Uchida, N., Hendel, A., Narla, A., Majeti, R., Weinberg, K. I., & Porteus, M. H.
- Affiliations
- Stanford University (US)
- Institute for Stem Cell Biology and Regenerative Medicine (US)
- Stanford Medicine (US)
- Corresponding author
- Porteus, Matthew H.
- ORCID
- Venue
- Nature
- Published
- 2016-11-07
- Volume
- 539
- Issue
- 7629
- Pages
- 384-389
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC5898607
- OpenAlex
- W2547418311
- Semantic Scholar
- 91eb4c33902b14df9b2974a4ce8dc6e3c3a02125
- Cited by
- 864
- References
- 50
- Citations by year
- 2026: 45 · 2025: 75 · 2024: 80 · 2023: 93 · 2022: 76 · 2021: 120 · 2020: 93 · 2019: 90 · 2018: 99 · 2017: 89 · 2016: 4
- FWCI
- 48.84
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institutes of Health (5r01ai120766-02, R01-AI120766)
- National Eye Institute (PN2EY018244)
- National Institute of General Medical Sciences (T32GM007266)
- National Institute of Allergy and Infectious Diseases (R01-AI120766, R01AI097320)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Keywords
- CRISPR/Cas9 genome editing, beta-globin gene, hematopoietic stem cells, sickle cell disease, beta-thalassemia, homologous recombination, adeno-associated virus vectors, Cas9 ribonucleoprotein, autologous transplantation, reporter genes
- MeSH terms
- Gene Editing, Dependovirus, Alleles, Anemia, Sickle Cell, Animals, Cell Differentiation, Cell Separation, Erythrocytes, Female, Flow Cytometry, Hematopoietic Stem Cells, Humans, Microspheres, Mutation, RNA, Messenger, Genetic Therapy, Mice, SCID, Mice, Inbred NOD, beta-Thalassemia, Genes, Reporter, Gene Targeting, Antigens, CD34, Cell Lineage, beta-Globins, Magnets, Homologous Recombination, CRISPR-Cas Systems, CRISPR-Associated Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
